Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) - Total Liabilities

Latest as of June 2025: CN¥4.70 Billion CNY ≈ $688.14 Million USD

Based on the latest financial reports, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has total liabilities worth CN¥4.70 Billion CNY (≈ $688.14 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Hunan Dajiaweikang Pharmaceutical Indust to assess how effectively this company generates cash.

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Total Liabilities Trend (2019–2024)

This chart illustrates how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Hunan Dajiaweikang Pharmaceutical Indust to evaluate the company's liquid asset resilience ratio.

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Competitors by Total Liabilities

The table below lists competitors of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
GFPT Public Company Limited BK:GFPT	Thailand	฿6.34 Billion
Aura Biosciences Inc NASDAQ:AURA	USA	$33.36 Million
Xinjiang West Animal Husbandry SHE:300106	China	CN¥561.20 Million
Shape Australia Corporation Ltd AU:SHA	Australia	AU$238.37 Million
Minfeng Special Paper Co Ltd SHG:600235	China	CN¥1.52 Billion
Tianjin Motimo Membrane Tech SHE:300334	China	CN¥360.93 Million
InPlay Oil Corp TO:IPO	Canada	CA$759.47 Million

Liability Composition Analysis (2019–2024)

This chart breaks down Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301126 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.17	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.68	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.72	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2024)

The table below shows the annual total liabilities of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥4.33 Billion ≈ $633.54 Million	+23.84%
2023-12-31	CN¥3.50 Billion ≈ $511.58 Million	+65.36%
2022-12-31	CN¥2.11 Billion ≈ $309.37 Million	+60.76%
2021-12-31	CN¥1.32 Billion ≈ $192.45 Million	+13.33%
2020-12-31	CN¥1.16 Billion ≈ $169.82 Million	+11.82%
2019-12-31	CN¥1.04 Billion ≈ $151.86 Million	--

About Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd

SHE:301126 China Pharmaceutical Retailers

Market Cap

$357.38 Million

CN¥2.44 Billion CNY

Market Cap Rank

#14231 Global

#4477 in China

Share Price

CN¥11.89

Change (1 day)

+1.28%

52-Week Range

CN¥10.22 - CN¥14.35

All Time High

CN¥36.14